Slingshot members are tracking this event:

US FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Advanced Liver Disease, Sofosbuvir, Ledipasvir, Child-pugh A, Hcv Genotype 1-infected, Decompensated Cirrhosis, Hcv/hiv-1 Coinfection, 4 Liver Transplant Recipients, Genotype 1